Ruxolitinib and abatacept to prevent GVHD after haplo transplant
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these blood cancers: AML, ALL, MDS, lymphoma, Hodgkin disease, or myelofibrosis that is in remission or has low blast counts.
- You must have a family member who is a half-match (haploidentical) donor, like a sibling, child, cousin, nephew, or parent, who is healthy and at least 18 years old.
- You cannot have had a stem cell transplant from a donor before (but an autologous transplant using your own cells is okay).
- You must not have donor-specific antibodies that could attack the donor stem cells.
- Your organs (liver, kidneys, lungs, heart) must be working well enough, and you must be in generally good health (ECOG score 0-2).
- Women who can have children and men must agree to use effective birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
This trial tests whether starting ruxolitinib early, guided by a blood marker, can prevent acute graft-versus-host disease (aGVHD) after a stem cell transplant. It's for people who have already had a transplant and are at risk for this complication.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
Hear when a new Graft Vs Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.